Publications 2009

  1. Bunupuradah T, Puthanakit T, Pancharoen C, Butterworth O, Phanuphak P, Ananworanich J. Henoch-Schönlein purpura and thrombocytopenia after planned antiretroviral treatment interruption in a Thai girl with HIV infection. Int J Infect Dis. 2009 Jan;13(1):e31-3. doi: 10.1016/j.ijid.2008.05.1225. Epub 2008 Aug 6.
  2. Avihingsanon A, Hemachandra A and van der Lugt J. Antiretroviral therapy for HIV-associated tuberculosis. Asian biomedicine. 2009 Feb;3(1):73-87.
  3. Kerr S and Phanuphak P. An Asian perspective on HIV/AIDS. Asian biomedicine. 2009 Feb;3(1):9-14.
  4. Van der Lugt J and Avihingsanon A. Clinical pharma­cology and pharmacokinetics of antiretrovirals in Asia. Asian biomedicine. 2009 Feb;3(1):53-62.
  5. Alter G, Ananworanich J, Pantophlet R, RybickiEP, Buonaguro L. Report on the AIDS Vaccine 2008 Conference. Hum Vaccin. 2009 Mar;5(3):119-25. Epub 2009 Mar 8.
  6. Avihingsanon A, Van der Lugt J, Kerr SJ, Gorowara M, Chanmano S, Ohata P, Lange J, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K. A Low Dose of Ritonavir-Boosted Atazanavir (200/100 mg) Provides Adequate Pharmacokinetics Parameters in Thai HIV-1 Infected Adults. Clin Pharmacol Ther. 2009 Apr;85(4):402-8. doi: 10.1038/clpt.2008.244. Epub 2008 Dec 31.
  7. Walmsley S, Avihingsanon A, Slim J, Ward D, Rux­rungtham K, Brunetta J, Bredeek UF, Jayaweera D, Guittari CJ, Larson P, Schutz M, Raffi F. Gemini: a non-inferiority study of saquinavir/ritonavir vs lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):367-74. doi: 10.1097/QAI.0b013e318198a815.
  8. Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, Chang J, Dore GJ, Price P, Visvanathan K, French M, Ruxrungtham Kand Lewin SR. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis. 2009 Apr 1;199(7):974-81. doi: 10.1086/597276.
  9. Duncombe C, Avihingsanon A, Hemachandra A, van der Lugt J, Ananworanich J, Ohata J, Puthanakit T, Bunupuradah T, Ruxrungtham K. The 12th Bangkok International Symposium on HIV Medicine. HIV Therapy. 2009 Apr;3(3):225-8.
  10. Lewin SR, Ribeiro R, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B viruscoinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754.
  11. Calmy A, Nguyen A, Montecucco F, Gayet-Ageron A, Burger F, Mach F, Carr A, Ubolyam S, Hirschel Band Ananworanich J for STACCATO study team. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009 May 15;23(8):929-39.
  12. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009 Jun;28(6):488-92.
  13. van der Lugt J, Gorowara M, Avihingsanon A, Burger D, Ananworanich J, Sringam K, Kerr S, Wit F, Lange J and Ruxrungtham K. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. AIDS. 2009 Jun 1;23(9):1176-9. doi: 10.1097/QAD.0b013e32832b4461.
  14. Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, Iser D, Slavin J, Burana­praditkun S, Marks P, Matthews G, Cooper DA, Kent SJ, Cameron PU, Sasadeusz J, Desmond P, Locarnini S, Dore GJ, Ruxrungtham K, Lewin SR. Impaired quality of the HBV-specific T-cell response in HIV-1-HBV co-infection. J Virol. 2009 Aug;83(15):7649-58. doi: 10.1128/JVI.00183-09. Epub 2009 May 20.
  15. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.
  16. Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, Chen YM, Oka S, DeLong A, SayerD, Smith J, Dax EM, Law M; TAQAS Laboratory Network. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods. 2009 Aug;159(2):185-93. doi: 10.1016/j.jviromet.2009.03.016. Epub 2009 Mar 26.
  17. Sohn AHand Ananworanich J. HAART for children with treatment failure. HIV Therapy. 2009 Sep;3(5):485-99.
  18. Nüesch R, Gayet-Ageron A, Chetchotisakd P, Pra­sithsirikul W, Kiertiburanakul S, Munsakul W, Rak­sakulkarn P, Tansuphasawasdikul S, Chautrakarn S, Ruxrungtham K, Hirschel B, Ananworanich J. and the STACCATO study group. The Impact of Combina­tion Antiretroviral Therapy and its Interruption on Anxiety, Stress, Depression and Quality of Life in Thai Patients. Open AIDS J. 2009 Sep 15;3:38-45. doi: 10.2174/1874613600903010038.
  19. Manosuthi W, Sungkanuparph S, Tantanathip P, Mankatitham W, Lueangniyomkul A, Thongyen S, Eampokarap B, Uttayamakul S, Suwanvattana P, Kaewsaard S, Ruxrungtham K; for the N2RStudy Team. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob Agents Chemother. 2009 Oct;53(10):4545-8. doi: 10.1128/AAC.00492-09. Epub 2009 Aug 10.
  20. INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175.
  21. Falster K, Choi JY, Donovan B, Duncombe C, Mulhall B, Sowden D, Zhou J, Law MG; on behalf of the Australian HIV Observational Database, the TREAT Asia HIV Observational Database. AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS. 2009 Nov 13;23(17):2323-36. doi: 10.1097/QAD.0b013e328331910c.
  22. Manosuthi W, Van Tieu H, Tantanathip P, Mankatitham W, Lueangniyomkul A, Ananworanich J, Anchalee Avihingsanon A, Siangphoe U, Klongugkara S, Thawornwan U, Suntisuklappon B, Sungkanuparph S, for the N2RStudy Team. Clinical Case Definition and Manifestations of Paradoxi­cal Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. AIDS. 2009 Nov 27;23(18):2467-71. doi: 10.1097/QAD.0b013e32832f7b59.
  23. Hill A, van der Lugt J, Sawyer W, Boffito M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetics trials. AIDS. 2009 Nov 13;23(17):2237-45. doi: 10.1097/QAD.0b013e328332c3a5.
  24. Van Tieu H, Ananworanich J, Avihingsanon A, Apateerapong W, Sirivichayakul S, Klongutkara S, Boonchokchai B, Siangphoe U, Hammer S, Manosuthi W. Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1083-9. doi: 10.1089/aid.2009.0055.
  25. PENTA Steering Committee1, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, Bunupuradah T, Hainaut M, Della Negra M, Pena MJ, Amador JT, Gattinara GC, Compagnucci A, Faye A, Giaquinto C, Gibb DM, Gandhi K, Forcat S, Buckberry K, Harper L, Königs C, Patel D, Bastiaans D. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009 Nov;10(10):591-613. doi: 10.1111/j.1468-1293.2009.00759.x.
  26. Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob Chemother. 2009 Nov;64(5):1080-6. doi: 10.1093/jac/dkp322. Epub 2009 Sep 2.
  27. Li AH, Phanuphak N, Sahasrabuddhe VV, Chai­thongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der LugtJ, Avihingsanon A, Ruxrungtham K, Shikuma C, Phanuphak P, Ananworanich J. Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand. Sex Transm Infect. 2009 Dec;85(7):503-7. doi: 10.1136/sti.2009.036707. Epub 2009 Jun 11.
  28. Duncombe C, Ananworanich J, Phanuphak N, Vermund SH. Evidence-based Strategies for Preventing HIV Transmission and the Thailand Perspective. Asian Biomedicine. 2009;3(1):39-51.
  29. Ruxrungtham K. HIV Immunology and Clinical Implica­tions. In: Fundamental Global HIV Medicine. Mayo Clinic (In press) 2009.
  30. van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, Ruxrungtham R. Plasma concentrations of generic lopinavir/ritonavir in HIV-1 infected individuals. Antivir Ther. 2009;14(7):1001-4. doi: 10.3851/IMP1410.
  31. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthai­song T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J; HIV-NAT 017 Study Team. Safety and efficacy of a double boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther. 2009;14(2):241-8.
  32. van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, Wyen C, Schutz M, Koopmans P, Ruxrungtham K, Richter C, Burger D; SARAstudy team. The pharmacokinetic, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther. 2009;14(3):443-50.